Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016

  • ID: 3753846
  • Drug Pipelines
  • 50 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Novartis AG
  • Sanofi
  • MORE
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016

Summary

‘Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016’, provides in depth analysis on Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
- The report reviews Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Novartis AG
  • Sanofi
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) Overview

Therapeutics Development

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Stage of Development

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Therapy Area

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Indication

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Companies

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Companies Involved in Therapeutics Development

Daiichi Sankyo Company, Limited

Galmed Pharmaceuticals Ltd.

GlaxoSmithKline Plc

Johnson & Johnson

Novartis AG

Sanofi

Xenon Pharmaceuticals Inc.

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Drug Profiles

Aramchol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-1940029 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-224 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEN-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Dormant Projects

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Discontinued Products

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Featured News & Press Releases

Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease

Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study

Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne

Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease

Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial

Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America

Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States

Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production

Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers

Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones

Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH

Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events

Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders

Jul 08, 2014: Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal

Jun 09, 2014: Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Pipeline by Galmed Pharmaceuticals Ltd., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Sanofi, H1 2016

Pipeline by Xenon Pharmaceuticals Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Daiichi Sankyo Company, Limited
Galmed Pharmaceuticals Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Novartis AG
Sanofi
Xenon Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll